For research use only. Not for therapeutic Use.
Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC50 of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657[1].
| Catalog Number | I045031 |
| CAS Number | 1439399-45-7 |
| Synonyms | N-[6-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide |
| Molecular Formula | C19H19F3N6O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H19F3N6O2S/c20-19(21,22)30-14-6-3-4-12(10-14)11-16(29)24-15-9-8-13(25-26-15)5-1-2-7-17-27-28-18(23)31-17/h3-4,6,8-10H,1-2,5,7,11H2,(H2,23,28)(H,24,26,29) |
| InChIKey | SXFQBUKKIKMRPM-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC(=C1)OC(F)(F)F)CC(=O)NC2=NN=C(C=C2)CCCCC3=NN=C(S3)N |
| Reference | [1]. Mark K. Bennett, et al. Treatment of cancer with heterocyclic inhibitors of glutaminase. WO2014089048A1. |
